Chelohart
Research OnlyA cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Heart cytamin · Cardiac peptide supplement · A-14 heart peptides
Mostly preclinical · 1 human study
- Preclinical
- 80%
- Human research
- 20%
Based on 5 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
Mechanism of Action
Chelohart is a cytamin-class supplement containing peptide complexes derived from cardiac (heart) tissue of young animals. It belongs to the Khavinson bioregulatory peptide framework developed at the St. Petersburg Institute of Bioregulation and Gerontology.
Proposed Mechanisms
- Myocardial Support — Claimed to contain tissue-specific peptides that support cardiac muscle cell function and metabolism
- Cardiac Tissue Regulation — Proposed bioregulatory effects on cardiac tissue gene expression via short peptide signaling
- Cardioprotection — Marketed for age-related cardiac support within the Khavinson bioregulator framework
How Cytamins Work (Theoretical)
Cytamins are oral supplements containing tissue-specific peptide complexes extracted from animal organs. The Khavinson theory proposes that these short peptides (2-4 amino acids) survive digestion, reach target tissues, and regulate gene expression by interacting with DNA promoter regions. This mechanism remains unvalidated by Western research standards.
Relationship to Cardiogen
Chelohart (tissue-derived cytamin) and Cardiogen (synthetic AED tripeptide) both target cardiac tissue within the Khavinson system. Cardiogen represents the synthetic, defined-sequence approach while Chelohart is the tissue extract complex. They are often marketed as complementary products.
Important Limitations
- NOT a defined peptide — contains complex mixture of tissue-derived peptides
- Oral peptide bioavailability is generally very low
- No Western clinical validation or independent replication
- No randomized controlled trials meeting international standards
- NOT a treatment for heart disease or any cardiac condition
- Not approved by any Western regulatory agency
- Primarily supported by Russian-language literature from a single research group
Cardiogen
CompatibleBoth target cardiac function within the Khavinson framework. Cardiogen is a synthetic AED tripeptide while Chelohart is a tissue-derived cytamin supplement. Often marketed together for cardiac support.
Vesugen
CompatibleBoth target cardiovascular system — Vesugen is synthetic KED tripeptide for vascular endothelium, Chelohart is tissue-derived for cardiac muscle.
Ventfort
CompatibleComplementary cardiovascular targets — Ventfort for blood vessels, Chelohart for heart tissue. Both are cytamin-class supplements.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Chelohart
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01 · Evaxion EVX-01
EVX-01 is an investigational, patient-specific neoantigen peptide vaccine studied with anti-PD-1 therapy in advanced melanoma. Two small single-arm cohorts show vaccine-specific T-cell responses and observed tumor responses, but they cannot establish how much EVX-01 adds to checkpoint treatment.
Livagen
KED · Lys-Glu-Asp · Hepatogen
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.